Veracyte (VCYT) to See Possible Medicare Payment Cut; Leerink Partners Cuts Price Target to $11
Tweet Send to a Friend
Leerink Partners maintained an Outperform rating on Veracyte, Inc (NASDAQ: VCYT), and cut the price target to $11.00 (from $13.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
